Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2

Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2

Alzheimer's disease, a multifactorial incurable disorder, is mainly characterised by progressive neurodegeneration, extracellular accumulation of amyloid-β protein (Aβ), and intracellular aggregation of hyperphosphorylated tau protein. During the last years, Aβ oligomers have been claimed to be...

Full description

Bibliographic Details
Main Authors: Sarah Schemmert, Elena Schartmann, Dominik Honold, Christian Zafiu, Tamar Ziehm, Karl-Josef Langen, Nadim Joni Shah, Janine Kutzsche, Antje Willuweit, Dieter Willbold
Format: Article
Language:English
Published: Elsevier 2019-04-01
Series:Neurobiology of Disease
Subjects:
Alzheimer's disease
Oral treatment
Amyloid β (Aβ) oligomers
d-enantiomeric peptides
Motor neurodegenerative phenotype
TBA2.1
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996118307320

Internet

http://www.sciencedirect.com/science/article/pii/S0969996118307320

Similar Items